Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors

Inclusion Criteria: 1. Aged 18 to 75 years, male or female; 2. Estimated life expectancy \> 12 weeks; 3. Pathologically/histologically confirmed diagnosis of advanced G/GEJ adenocarcinoma or pancreatic cancer or other digestive system malignancies G/GEJA: refractory to or intolerable of at least 2 prior lines of treatment; HER2+ subjects must be refractory or intolerable of anti-HER2 treatment PC: refractory to or intolerable of at least 1 prior line of treatment; 4. Positive expression of CLDN18.2 in tumor tissue specimens; 5. According to the RECIST 1.1, there is measurable or unmeasurable tumor lesions; 6. ECOG physical status score 0 \~ 1 at screening, within 24 hours prior to apheresis; 7. Sufficient venous access for leukapheresis (central venous catheter) 8. Subjects should have adequate organ functions before screening : 9. Women of childbearing age (WOCB) be willing to use effective and reliable method of contraception (annual failure\<1%) for at least 1 year after last infusion, and must refrain from donating sperms/eggs 10. Men who have actively sexual intercourse with women with child-bearing potential, must agree to use barrier-based contraception if they have no vasectomy. Moreover, all men are absolutely forbidden to donate sperm within 1 year after receiving the last infusion. Exclusion Criteria: 1. High risks that may cause bleeding or perforation; 2. CNS metastasis, with or without related symptoms; 3. The presence of extensive lung metastases, or extensive liver metastases, or extensive bone metastases 4. History or current unstable or active digestive ulcers, gastrointestinal (GI) bleeding, GI obstruction; 5. Anti-tumor treatment for the investigational disease; treatment with anti-PD-1/PD-L1, anti-CTLA4, and any other immunotherapy or investigational therapy； 6. Prior treatment with any genetically modified cell therapy; 7. Treatment with systemic corticosteroids within 7 days prior to leukapheresis; 8. Prior solid organ transplantation, or allogeneic stem cell, or in the waiting list for organ transplantation; 9. Major surgical procedure or serious wound within 4 weeks prior to leukapheresis, or anticipation of need for a major surgical procedure during the study; 10. Positive serological tests of HIV, syphilis or HCV (subjects with positive HCV antibody but are negative for HCV RNA are eligible); 11. Any active or severe infection, incl. but not limited to active tuberculosis, HBV infection, etc.; 12. Active autoimmune disease; 13. Uncontrolled significant cardiovascular disease, pulmonary disease or CNS disease 14. History of malignancy other than investigational diseases within 3 years, with the exception of malignancies with a negligible risk of metastasis or death; 15. Pregnancy or lactating women; 16. History of allergic anaphylactic reactions to immunotherapy, and/or tocilizumab, cyclophosphamide, fludarabine or nab-paclitaxel, and/or CT048 components, or other history of severe allergic anaphylactic reactions ； 17. Blood oxygen saturation ≤95% before leukapheresis; 18. AEs from previous treatment that have not recovered to CTCAE ≤ grade 1, excluding hair loss, pigmentation, and other tolerable events and laboratory abnormalities permitted by the protocol;